RNA疗法在代谢性疾病治疗中的运用
The Use of RNA-Based Therapeutics in the Treatment of Metabolic Diseases
DOI: 10.12677/hjbm.2026.162022, PDF,   
作者: 童璐子云*：马来西亚理工大学理学院，马来西亚 新山；河南科技学院生命科学学院，河南 新乡；张守涛#：河南科技学院生命科学学院，河南 新乡；Kian Mau Goh#：马来西亚理工大学理学院，马来西亚 新山
关键词: RNA疗法；代谢性疾病；递送平台；靶向治疗；RNA Therapeutics； Metabolic Diseases； Delivery Platforms； Targeted Therapy
摘要: 代谢性疾病涉及多器官、多通路病理网络，现有药物治疗常需长期联合用药，且长期疗效与耐受性仍受限制。本文围绕RNA疗法在代谢性疾病中的研究进展，系统梳理小干扰RNA (siRNA)、反义寡核苷酸(ASO)、微小RNA (miRNA)及短发夹RNA (shRNA)的作用机制与技术特点，总结GalNAc偶联、脂质纳米颗粒(LNP)等主流递送平台的适用范围，并分别总结肥胖、2型糖尿病、MASLD/MASH和高脂血症的主要干预靶点及转化现状。综合分析表明，高脂血症因靶点集中且肝递送路径成熟转化程度较高；MASLD/MASH与肝靶向平台适配性强，具备较明确的推进基础；肥胖与糖尿病由于多组织参与，RNA疗法更适用于关键节点干预及联合策略。总体而言，递送效率、组织选择性与长期安全性仍是限制拓展适应症的主要问题。
Abstract: Metabolic diseases involve complex multi-organ and multi-pathway pathological networks, and current pharmacological treatments often rely on long-term combination therapies with limitations in sustained efficacy and tolerability. This review summarizes recent advances in RNA therapeutics for metabolic diseases, systematically outlining the mechanisms and technical features of small interfering RNA (siRNA), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and short hairpin RNA (shRNA). Major delivery platforms, including GalNAc conjugation and lipid nanoparticles (LNPs), are discussed with respect to their applicability and translational potential. In addition, key therapeutic targets and current progress are reviewed across obesity, type 2 diabetes mellitus, MASLD/MASH, and hyperlipidemia. Comparative analysis indicates that RNA-based therapies for hyperlipidemia have achieved the highest level of clinical translation due to well-defined targets and mature liver-directed delivery strategies. MASLD/MASH shows strong compatibility with hepatic targeting platforms and holds substantial translational promise, whereas obesity and type 2 diabetes involve multi-tissue regulation, making RNA therapeutics more suitable for intervention at critical regulatory nodes or as part of combination therapies. Overall, delivery efficiency, tissue selectivity, and long-term safety remain the major challenges limiting the expansion of RNA therapeutics to broader metabolic indications.
文章引用：童璐子云, 张守涛, Kian Mau Goh. RNA疗法在代谢性疾病治疗中的运用[J]. 生物医学, 2026, 16(2): 202-213. https://doi.org/10.12677/hjbm.2026.162022

参考文献

[1] Miranda, P.J., DeFronzo, R.A., Califf, R.M. and Guyton, J.R. (2005) Metabolic Syndrome: Definition, Pathophysiology, and Mechanisms. American Heart Journal, 149, 33-45. [Google Scholar] [CrossRef] [PubMed]
[2] Lillich, F.F., Imig, J.D. and Proschak, E. (2021) Multi-Target Approaches in Metabolic Syndrome. Frontiers in Pharmacology, 11, Article ID: 554961. [Google Scholar] [CrossRef] [PubMed]
[3] Pillarisetti, L. and K. Agrawal, D. (2025) Semaglutide: Double-Edged Sword with Risks and Benefits. Archives of Internal Medicine Research, 8, 1-13. [Google Scholar] [CrossRef] [PubMed]
[4] Yoo, H. (2024) Development of Orphan Drugs for Rare Diseases. Clinical and Experimental Pediatrics, 67, 315-327. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, A., Choi, Y.H. and Tu, M. (2020) RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacological Reviews, 72, 862-898. [Google Scholar] [CrossRef] [PubMed]
[6] Chery, J. (2016) RNA Therapeutics: RNAi and Antisense Mechanisms and Clinical Applications. Postdoc Journal, 4, 35-50. [Google Scholar] [CrossRef] [PubMed]
[7] Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) Passenger-Strand Cleavage Facilitates Assembly of siRNA into AgO2-Containing RNAi Enzyme Complexes. Cell, 123, 607-620. [Google Scholar] [CrossRef] [PubMed]
[8] Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., et al. (2020) Therapeutic siRNA: State of the Art. Signal Transduction and Targeted Therapy, 5, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
[9] Moore, C.B., Guthrie, E.H., Huang, M.T.H., et al. (2010) Short Hairpin RNA (shRNA): Design, Delivery, and Assessment of Gene Knockdown. Methods in Molecular Biology (Clifton., N.J.), 629, 141-158.
[10] O’Brien, J., Hayder, H., Zayed, Y. and Peng, C. (2018) Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Frontiers in Endocrinology, 9, Article No. 402. [Google Scholar] [CrossRef] [PubMed]
[11] Bartel, D.P. (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 116, 281-297. [Google Scholar] [CrossRef] [PubMed]
[12] Miller, C.M. and Harris, E.N. (2016) Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization. RNA & Disease (Houston, Tex.), 3, e1393.
[13] Finkel, R.S., Chiriboga, C.A., Vajsar, J., Day, J.W., Montes, J., De Vivo, D.C., et al. (2016) Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study. The Lancet, 388, 3017-3026. [Google Scholar] [CrossRef] [PubMed]
[14] Fogacci, F., Ferri, N., Toth, P.P., Ruscica, M., Corsini, A. and Cicero, A.F.G. (2019) Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 79, 751-766. [Google Scholar] [CrossRef] [PubMed]
[15] Khanduja, J.S., Calvo, I.A., Joh, R.I., Hill, I.T. and Motamedi, M. (2016) Nuclear Noncoding RNAs and Genome Stability. Molecular Cell, 63, 7-20. [Google Scholar] [CrossRef] [PubMed]
[16] Xin, R., Kim, E., Li, W.T., Wang-Rodriguez, J. and Ongkeko, W.M. (2025) Non-Coding RNAs: lncRNA, piRNA, and snoRNA as Robust Plasma Biomarkers of Alzheimer’s Disease. Biomolecules, 15, Article No. 806. [Google Scholar] [CrossRef] [PubMed]
[17] Lamb, Y.N. (2021) Inclisiran: First Approval. Drugs, 81, 389-395. [Google Scholar] [CrossRef] [PubMed]
[18] Adams, D., Gonzalez-Duarte, A., O’Riordan, W.D., Yang, C., Ueda, M., Kristen, A.V., et al. (2018) Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379, 11-21. [Google Scholar] [CrossRef] [PubMed]
[19] Arunachalam, P.S., Scott, M.K.D., Hagan, T., Li, C., Feng, Y., Wimmers, F., et al. (2021) Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans. Nature, 596, 410-416. [Google Scholar] [CrossRef] [PubMed]
[20] Estupiñán, H.Y., Baladi, T., Roudi, S., Munson, M.J., Bost, J., Gustafsson, O., et al. (2025) Design and Screening of Novel Endosomal Escape Compounds That Enhance Functional Delivery of Oligonucleotides in Vitro. Molecular Therapy Nucleic Acids, 36, Article ID: 102522. [Google Scholar] [CrossRef] [PubMed]
[21] Debacker, A.J., Voutila, J., Catley, M., Blakey, D. and Habib, N. (2020) Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy, 28, 1759-1771. [Google Scholar] [CrossRef] [PubMed]
[22] Du Rietz, H., Hedlund, H., Wilhelmson, S., Nordenfelt, P. and Wittrup, A. (2020) Imaging Small Molecule-Induced Endosomal Escape of siRNA. Nature Communications, 11, Article No. 1809. [Google Scholar] [CrossRef] [PubMed]
[23] Ma, Y., Li, S., Lin, X. and Chen, Y. (2024) A Perspective of Lipid Nanoparticles for RNA Delivery. Exploration, 4, Article ID: 20230147. [Google Scholar] [CrossRef] [PubMed]
[24] Wei, P., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., et al. (2024) Enhancing RNA-Lipid Nanoparticle Delivery: Organ-and Cell-Specificity and Barcoding Strategies. Journal of Controlled Release, 375, 366-388. [Google Scholar] [CrossRef] [PubMed]
[25] Zhou, J., Sun, L., Liu, L., Jia, Y., Han, Y., Shao, J., et al. (2022) Hepatic Macrophage Targeted siRNA Lipid Nanoparticles Treat Non-Alcoholic Steatohepatitis. Journal of Controlled Release, 343, 175-186. [Google Scholar] [CrossRef] [PubMed]
[26] Carrasco, M.J., Alishetty, S., Alameh, M., Said, H., Wright, L., Paige, M., et al. (2021) Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration. Communications Biology, 4, Article No. 956. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., et al. (2023) Viral Vectored Vaccines: Design, Development, Preventive and Therapeutic Applications in Human Diseases. Signal Transduction and Targeted Therapy, 8, Article No. 149. [Google Scholar] [CrossRef] [PubMed]
[28] Waehler, R., Russell, S.J. and Curiel, D.T. (2007) Engineering Targeted Viral Vectors for Gene Therapy. Nature Reviews Genetics, 8, 573-587. [Google Scholar] [CrossRef] [PubMed]
[29] Nisanov, A.M., Rivera de Jesús, J.A. and Schaffer, D.V. (2025) Advances in AAV Capsid Engineering: Integrating Rational Design, Directed Evolution and Machine Learning. Molecular Therapy, 33, 1937-1945. [Google Scholar] [CrossRef] [PubMed]
[30] Amiri, A., Bagherifar, R., Ansari Dezfouli, E., Kiaie, S.H., Jafari, R. and Ramezani, R. (2022) Exosomes as Bio-Inspired Nanocarriers for RNA Delivery: Preparation and Applications. Journal of Translational Medicine, 20, Article No. 125. [Google Scholar] [CrossRef] [PubMed]
[31] Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., et al. (2024) Exosome for mRNA Delivery: Strategies and Therapeutic Applications. Journal of Nanobiotechnology, 22, Article No. 395. [Google Scholar] [CrossRef] [PubMed]
[32] Kim, H.I., Park, J., Zhu, Y., Wang, X., Han, Y. and Zhang, D. (2024) Recent Advances in Extracellular Vesicles for Therapeutic Cargo Delivery. Experimental & Molecular Medicine, 56, 836-849. [Google Scholar] [CrossRef] [PubMed]
[33] Ferré, P. and Foufelle, F. (2007) Srebp-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective. Hormone Research in Paediatrics, 68, 72-82. [Google Scholar] [CrossRef] [PubMed]
[34] Kozak, L.P. and Anunciado-Koza, R. (2008) UCP1: Its Involvement and Utility in Obesity. International Journal of Obesity, 32, S32-S38. [Google Scholar] [CrossRef] [PubMed]
[35] Puigserver, P. (2005) Tissue-specific Regulation of Metabolic Pathways through the Transcriptional Coactivator Pgc1-α. International Journal of Obesity, 29, S5-S9. [Google Scholar] [CrossRef] [PubMed]
[36] D’Onofrio, N., Prattichizzo, F., Martino, E., Anastasio, C., Mele, L., La Grotta, R., et al. (2023) Mir-27b Attenuates Mitochondrial Oxidative Stress and Inflammation in Endothelial Cells. Redox Biology, 62, Article ID: 102681. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, Y., Chen, C., Liu, Y., Rao, S., Tan, Y., Qian, Y., et al. (2021) Neuronal Induction of Bone‐Fat Imbalance through Osteocyte Neuropeptide Y. Advanced Science, 8, Article ID: 2100808. [Google Scholar] [CrossRef] [PubMed]
[38] Akbari, P., Sosina, O.A., Bovijn, J., Landheer, K., Nielsen, J.B., Kim, M., et al. (2022) Multiancestry Exome Sequencing Reveals INHBE Mutations Associated with Favorable Fat Distribution and Protection from Diabetes. Nature Communications, 13, Article No. 4844. [Google Scholar] [CrossRef] [PubMed]
[39] Deaton, A.M., Dubey, A., Ward, L.D., Dornbos, P., Flannick, J., Yee, E., et al. (2022) Rare Loss of Function Variants in the Hepatokine Gene INHBE Protect from Abdominal Obesity. Nature Communications, 13, Article No. 4319. [Google Scholar] [CrossRef] [PubMed]
[40] Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., et al. (2022) BI 456906: Discovery and Preclinical Pharmacology of a Novel GCGR/GLP-1R Dual Agonist with Robust Anti-Obesity Efficacy. Molecular Metabolism, 66, Article ID: 101633. [Google Scholar] [CrossRef] [PubMed]
[41] Pawlos, A., Broncel, M., Woźniak, E. and Gorzelak-Pabiś, P. (2021) Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 26, Article No. 7213. [Google Scholar] [CrossRef] [PubMed]
[42] Liu, R., Mathieu, C., Berthelet, J., Zhang, W., Dupret, J. and Rodrigues Lima, F. (2022) Human Protein Tyrosine Phosphatase 1B (PTP1B): From Structure to Clinical Inhibitor Perspectives. International Journal of Molecular Sciences, 23, Article No. 7027. [Google Scholar] [CrossRef] [PubMed]
[43] Ullah, R., Rauf, N., Nabi, G., Yi, S., Yu-Dong, Z. and Fu, J. (2021) Mechanistic Insight into High-Fat Diet-Induced Metabolic Inflammation in the Arcuate Nucleus of the Hypothalamus. Biomedicine & Pharmacotherapy, 142, Article ID: 112012. [Google Scholar] [CrossRef] [PubMed]
[44] Teaney, N.A. and Cyr, N.E. (2023) FoxO1 as a Tissue-Specific Therapeutic Target for Type 2 Diabetes. Frontiers in Endocrinology, 14, Article ID: 1286838. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, Y., Liu, J., Zhu, S., Hu, S., Chen, X., Mandon, E., et al. (2025) miR-375 Protects against Acetaminophen-Induced Acute Liver Failure by Orchestrating Pharmacogene Expression. Molecular Therapy, 33, 4874-4888. [Google Scholar] [CrossRef] [PubMed]
[46] Wang, Y., Zhao, X., Zhang, L., Yang, C., Zhang, K., Gu, Z., et al. (2023) MicroRNA-34a Mediates High-Fat-Induced Hepatic Insulin Resistance by Targeting ENO3. Nutrients, 15, Article No. 4616. [Google Scholar] [CrossRef] [PubMed]
[47] Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., et al. (2024) NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications. Signal Transduction and Targeted Therapy, 9, Article No. 53. [Google Scholar] [CrossRef] [PubMed]
[48] van Gerwen, J., Shun-Shion, A.S. and Fazakerley, D.J. (2023) Insulin Signalling and GLUT4 Trafficking in Insulin Resistance. Biochemical Society Transactions, 51, 1057-1069. [Google Scholar] [CrossRef] [PubMed]
[49] Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J., et al. (2024) Oligonucleotide Therapies for Nonalcoholic Steatohepatitis. Molecular Therapy—Nucleic Acids, 35, Article ID: 102184. [Google Scholar] [CrossRef] [PubMed]
[50] Lee, E., Lee, J., Kim, D., Lee, Y., Jo, Y., Dao, T., et al. (2024) Loss of Srebp-1c Ameliorates Iron-Induced Liver Fibrosis by Decreasing Lipocalin-2. Experimental & Molecular Medicine, 56, 1001-1012. [Google Scholar] [CrossRef] [PubMed]
[51] Doi, H., Atsumi, J., Baratz, D. and Miyamoto, Y. (2023) A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 36, 300-308. [Google Scholar] [CrossRef] [PubMed]
[52] Ma, Y., Cai, H., Smith, J., Chu, C., Mercer, S.E., Boehm, S., et al. (2024) Evaluation of Antisense Oligonucleotide Therapy Targeting Hsd17b13 in a Fibrosis Mice Model. Journal of Lipid Research, 65, Article ID: 100514. [Google Scholar] [CrossRef] [PubMed]
[53] Duan, M., Chi, X., Xiao, H., Liu, X. and Zhuang, H. (2021) High-Normal Alanine Aminotransferase Is an Indicator for Liver Histopathology in HBeAg-Negative Chronic Hepatitis B. Hepatology International, 15, 318-327. [Google Scholar] [CrossRef] [PubMed]
[54] Luo, Y., Hou, Y., Zhao, W. and Yang, B. (2024) Recent Progress in Gene Therapy for Familial Hypercholesterolemia Treatment. iScience, 27, Article ID: 110641. [Google Scholar] [CrossRef] [PubMed]
[55] Watts, G.F., Schwabe, C., Scott, R., Gladding, P.A., Sullivan, D., Baker, J., et al. (2023) RNA Interference Targeting ANGPTL3 for Triglyceride and Cholesterol Lowering: Phase 1 Basket Trial Cohorts. Nature Medicine, 29, 2216-2223. [Google Scholar] [CrossRef] [PubMed]
[56] Hu, N., Chen, C., Wang, J., Huang, J., Yao, D. and Li, C. (2021) Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-Signaling Pathway and HMGCR Expression in the Liver. International Journal of Molecular Sciences, 22, Article No. 11107. [Google Scholar] [CrossRef] [PubMed]
[57] Ruan, H., Dou, D., Lu, J., Xiao, X., Gong, X. and Zhang, X. (2025) Off-Target Effects of Oligonucleotides and Approaches of Preclinical Assessments. SLAS Discovery, 35, Article ID: 100254. [Google Scholar] [CrossRef] [PubMed]
[58] Roberts, T.C., Langer, R. and Wood, M.J.A. (2020) Advances in Oligonucleotide Drug Delivery. Nature Reviews Drug Discovery, 19, 673-694. [Google Scholar] [CrossRef] [PubMed]
[59] Sparmann, A. and Vogel, J. (2023) RNA-Based Medicine: From Molecular Mechanisms to Therapy. The EMBO Journal, 42, e114760. [Google Scholar] [CrossRef] [PubMed]
[60] Ali Zaidi, S.S., Fatima, F., Ali Zaidi, S.A., Zhou, D., Deng, W. and Liu, S. (2023) Engineering siRNA Therapeutics: Challenges and Strategies. Journal of Nanobiotechnology, 21, Article No. 381. [Google Scholar] [CrossRef] [PubMed]
[61] Egli, M. and Manoharan, M. (2023) Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics. Nucleic Acids Research, 51, 2529-2573. [Google Scholar] [CrossRef] [PubMed]
[62] Chahal, G., Helbig, K., Parton, R. and Monson, E. (2026) The Biology of Endosomal Escape: Strategies for Enhanced Delivery of Therapeutics. ACS Nano, 20, 1789-1813. [Google Scholar] [CrossRef] 
[63] Tang, Q. and Khvorova, A. (2024) RNAi-Based Drug Design: Considerations and Future Directions. Nature Reviews Drug Discovery, 23, 341-364. [Google Scholar] [CrossRef] [PubMed]
[64] Seyhan, A.A. (2024) Trials and Tribulations of MicroRNA Therapeutics. International Journal of Molecular Sciences, 25, Article No. 1469. [Google Scholar] [CrossRef] [PubMed]
[65] Bindal, G., Misra, C.S., Singh, M., Rangu, S.S., Pandey, N. and Rath, D. (2025) High-Throughput CRISPR Approaches: New Solutions for Challenging Problems. TrAC Trends in Analytical Chemistry, 189, Article ID: 118245. [Google Scholar] [CrossRef] 
[66] Fontanellas, A., Berraondo, P., Urigo, F., Jericó, D., Martini, P.G.V., Pastor, F., et al. (2025) RNA-Based Therapies in Liver Metabolic Diseases. Gut, 74, 1514-1527. [Google Scholar] [CrossRef] [PubMed]

为你推荐